We allocate a small, but growing part of our portfolio to investing in unique and innovative products and services with global growth opportunities.

These investments help diversify the portfolio. Diversification creates the right mix of different types of investments, which is one of the main drivers of risk and returns. It also gives us broad exposure to all investment markets, giving our members unique points of difference that add value over and above the market return.

Global Health Opportunities (GHO) Capital fund 

We are invested in Global Health Opportunities (GHO) Capital fund, which invests in the European healthcare sector, with a focus in high growth segments.  Our investment in GHO gives us access to the highly attractive and underpenetrated European healthcare market opportunity. Our conviction to invest also lies in the GHO team who come from mixture of private equity, investment banking and operational backgrounds. The team has extensive access to European healthcare companies with strong relationships at all levels, from operational manager to board directors. 

Through our investment in GHO, we have acquired a number of market leading healthcare companies, two of which are highlighted below:

Caprion Biosciences (Caprion): Caprion is a world leading clinical research organisation that provides state-of-the-art platforms in immune and proteomics (large scale study of proteins) monitoring to the pharmaceutical and biotechnology industries. Caprion also develops diagnostic products targeting cancer, metabolic and infectious diseases.

Envision Pharma Group (Envision Pharma): Envision Pharma is an international innovative global technology and scientific communication company serving pharmaceutical, biotechnology and medical device companies. Initially focusing on reinventing the way biopharma companies managed their global data communications programs through the use of smart technology, Envision has evolved to become a leading provider of communication services and medical affairs solutions encompassing all aspects of scientifically-driven data dissemination activities required to support the industry.

Investment date: June 2015

Returns to members: Returns will come from the expected growth in the value of GHO’s portfolio companies.

Where this investment fits in our portfolio: Pre-mixed options (excluding the Diversified SRI option); Alternatives (Private equity sector).

 

 

Quotient Sciences

In the health sector, we have invested in UK-based company Quotient Sciences. Quotient Sciences is an innovative pharmaceutical company that integrates drug formulation, real-time manufacturing, and in-patient clinical testing all in one location, allowing for faster clinical timelines. 

Through this investment, we are supporting the delivery of new medicines that enable faster clinical timelines for the pharmaceutical industry.

Investment date: November 2015

Returns to members: Returns will come from the expected growth in the value of the business.

Where this investment fits in our portfolio: Pre-mixed options (excluding the Diversified SRI option); Alternatives (Private equity sector).

Blackbird Ventures

Blackbird Ventures is an IT-focused venture capital fund headquartered in Sydney, that provides equity to Australian companies wanting to be the best in the world.

Through our investment in the Blackbird Ventures 2015 Fund and Blackbird Ventures 2018 Fund, we have exposure to a number of innovative companies such as Fleet Space, See-Mode Technologies and Applied.

1. Fleet Space

Blackbird has recently invested in Fleet Space. Based in Adelaide, South Australia, Fleet Space are experts in remote connectivity systems, providing internet in hard to reach places through micro, or nano-satellites, to be used, primarily, for industrial work.

Fleet Space has recently transmitted data from sensors on the Great Barrier Reef that monitor the level of bleaching directly to the marine biologists’ phones and desktop computers. Previously, biologists had to travel to the sensors on a weekly basis.

Investment date: February 2017, through the Blackbird 2015 Core Fund.

Returns to members: Returns will come from the expected growth in the value of Blackbird’s portfolio companies.

Where this investment fits in our portfolio: Pre-mixed options (excluding the Diversified SRI option); Alternatives (Private equity sector).

2. See-Mode Technologies

See-Mode Technologies (See-Mode) is a software company using advanced technology to improve the outlook for stroke victims by reducing the likelihood of repeated strokes.

See-Mode uses artificial intelligence and computer modelling to analyse medical images, to help neurologists improve how they assess the risks faced by stroke patients and to recommend a tailored course of treatment to prevent future strokes.

Investment date: February 2017, through the Blackbird 2015 Core Fund.

Where this sits in our investment portfolio: Private Equity asset allocation (part of the pre-mixed options other than Diversified SRI).

Returns to members: Returns will come from the expected growth in the value of these companies.

See-Mode’s software will enable clinicians to spot warning signs of an imminent stroke and help prevent it.

3. Applied

Applied is a recruitment platform designed by leading behavioural scientists to remove bias and improve predictive validity in the hiring process.

The platform aims to make hiring smart, fair and easy. It uses research and data science to help organisations hire the best person for the job, irrespective of their background, gender or ethnicity. It does this by enabling extensive ‘blinding’ of personal and social demographic details such as the name, university and income of candidates, to mitigate bias and better identify suitable talent.

Investment date: December 2018

Where this sits in our investment portfolio: Private Equity asset allocation (part of the pre-mixed options other than Diversified SRI).

Returns to members: Returns will come from the expected growth in the value of these companies.

Not only does the Applied platform help recruitment be fairer and faster, it leads to improved retention, which could cut recruitment administration time by up to 95%. The platform has been shown to identify and successfully appoint three times as many high-performing ethnically diverse candidates as traditional processes.

HaloDoc

We recently partnered with Openspace Ventures, a Singapore-based venture capital fund that focuses on early-stage technology investments in Southeast Asia.

An investment Openspace has made is HaloDoc, an Indonesian mobile healthcare platform that connects users to a large network of GPs, specialists, pharmacies and other healthcare providers via chat, video and voice calls.

HaloDoc’s core services include Contact Doctor, a teleconsultation service, Apotik Antar, a pharmacy delivery service and Labs, a home lab service. HaloDoc serves over 2 million patients with more than 10,000 daily transactions.

Investment date: March 2019

Where this sits in our investment portfolio: Private Equity asset allocation (part of the pre-mixed options other than Diversified SRI).

Returns to members: Returns will come from the expected growth in the value of these companies.

For many Indonesians, seeing a specialist doctor can be difficult, especially in rural areas where qualified doctors and medicine are hard to find. HaloDoc aims to revolutionise access to quality healthcare services for millions of Indonesians.

The investments included are accurate as at 1 September 2018.

All investments carry risk, and First State Super does not guarantee the payment of income or performance of the investments referenced above.